45 completed, 25 terminated, 7 unknown, 5 recruiting. 56 Phase 2, 38 Phase 1, 4 Phase 3, 3 Not applicable, 1 Phase 4.
Follow Myelodysplastic Syndrome (MDS): new trials by email Literature Review of Myelodysplastic Syndrome (MDS) trials Research Report on Myelodysplastic Syndrome (MDS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) BLEX 404 Oral Liquid - Myelodysplastic Syndrome (MDS) | Phase 2 | Not yet recruiting | BioLite, Inc. | 52 | 2027-01-01 | 2026-04-13 |
| A Phase 2 Study of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome Following Conditioning With Fludarabine and Total Body Irradiation 800 cGy Allogeneic Stem Cell Transplant - MDS, Myelodysplastic Syndrome MDS | Phase 2 | Not yet recruiting | Ronald Paquette | 20 | 2026-12-01 | 2026-10-27 |
| Patient Reported Outcomes and Patient Voice Among Patients Diagnosed With Low Risk Myelodysplastic Syndrome (LR-MDS) or Unexplained Anemia In Japan Health-related quality of life questionnaires, Qualitative interviews - Myelodysplastic Syndrome (MDS) | Completed | Bristol-Myers Squibb | 56 | 2025-05-13 | 2026-05-26 | |
| Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics Treosulfan, Fludarabine - Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS) | Phase 1 | Completed | medac GmbH | 20 | 2024-02-01 | 2026-05-20 |
| A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies PRT2527, Zanubrutinib, Venetoclax - Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Phase 1 | Completed | Prelude Therapeutics Incorporated | 86 | 2023-09-12 | 2026-01-26 |
| A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects LP-001 Dose 1 (Single), LP-001 Dose 2 (Single), LP-001 Dose 3 (Single) - Myelodysplastic Syndrome (MDS) | Phase 1 | Completed | Longbio Pharma | 68 | 2022-09-03 | 2025-12-15 |
| Refine and Assess the Readability of Patient, Carer, and Clinician Treatment Preference in Myelodysplasia Questionnaire Carer Treatment Preference Myelodysplasia Questionnaire, Clinician Treatment Preference Myelodysplasia Questionnaire, Patient Treatment Preference Myelodysplasia Questionnaire - Myelodysplastic Syndrome (MDS) | Completed | Otsuka Australia Pharmaceutical Pty Ltd | 16 | 2022-06-28 | 2023-04-18 | |
| STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS MBG453, Azacitidine, Decitabine - Myelodysplastic Syndrome (MDS) | Phase 2 | Terminated | Novartis Pharmaceuticals | 39 | 2022-03-17 | 2025-10-16 |
| ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN ADCT-301 - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 2 | Terminated | Gwynn Long, M.D. | 3 | 2021-12-07 | 2026-05-01 |
| CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) CLN-049 - Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 1 | Recruiting | Cullinan Therapeutics Inc. | 60 | 2021-11-18 | 2026-01-16 |
| Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome Lemzoparlimab, Azacitidine, Venetoclax - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 1 | Terminated | AbbVie | 40 | 2021-06-25 | 2024-02-26 |
| A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants sabatolimab, azacitidine, venetoclax - Myelodysplastic Syndrome (MDS) | Phase 2 | Terminated | Novartis Pharmaceuticals | 20 | 2021-05-31 | 2025-10-09 |
| Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations LY3410738, Venetoclax, Azacitidine - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 1 | Active not recruiting | Eli Lilly and Company | 260 | 2020-11-19 | 2026-07-22 |
| A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome ASTX030 (AZA + CED) - Myelodysplastic Syndrome (MDS) | Phase 1 | Recruiting | Taiho Pharmaceutical Co., Ltd. | 59 | 2020-10-30 | 2026-08-10 |
| Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome Venetoclax, Azacitidine, Placebo - Myelodysplastic Syndrome (MDS) | Phase 3 | Active not recruiting | AbbVie | 531 | 2020-09-10 | 2026-05-06 |
| Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT Infusion of NEXI-001 T Cells - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 1 / Phase 2 | Unknown | NexImmune Inc. | 22 | 2020-02-20 | 2024-01-16 |
| A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies TQB3455 tablet+Azacitidine for Injection - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 1 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 100 | 2019-10-22 | 2024-08-13 |
| A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome FF-10501-01, Azacitidine - Myelodysplastic Syndrome (MDS) | Phase 2 | Withdrawn | Fujifilm Pharmaceuticals U.S.A., Inc. | 2019-10-01 | 2024-12-05 | |
| CPX-351 Therapy for MDS After Hypomethylating Agent Failure CPX-351 - Myelodysplastic Syndrome (MDS) | Phase 2 | Terminated | Case Comprehensive Cancer Center | 4 | 2019-07-25 | 2024-08-15 |
| Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN Venetoclax, Fludarabine, Busulfan - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 1 | Active not recruiting | Jacqueline Garcia, MD | 102 | 2018-10-24 | 2026-05-20 |
Showing 20 of 94. Sign in to see all of them.
Myelodysplastic Syndromes (94) · Leukemia, Myeloid, Acute (53) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (20) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (16) · Leukemia (15) · Lymphoma, Non-Hodgkin (14) · Hodgkin Disease (10) · Hematologic Neoplasms (7) · Leukemia, Lymphocytic, Chronic, B-Cell (7) · Leukemia, Myelomonocytic, Chronic (7) · Leukemia, Myelomonocytic, Juvenile (6) · Lymphoma (6) · Myeloproliferative Disorders (6) · Anemia, Aplastic (5) · Recurrence (5)
Hemic and Lymphatic Diseases (94) · Bone Marrow Diseases (93) · Hematologic Diseases (92) · Neoplasms (59) · Neoplasms by Histologic Type (59) · Leukemia, Myeloid (58) · Leukemia (45) · Pathological Conditions, Signs and Symptoms (29) · Immune System Diseases (28) · Disease Attributes (27) · Immunoproliferative Disorders (27) · Lymphoproliferative Disorders (27) · Pathologic Processes (27) · Lymphatic Diseases (26) · Chronic Disease (23)
Azacitidine (12) · fludarabine (11) · fludarabine phosphate (11) · Busulfan (7) · Cyclophosphamide (7) · Melphalan (7) · Filgrastim (6) · Granulocyte Colony-Stimulating Factor (6) · Thiotepa (6) · venetoclax (6) · Antilymphocyte Serum (5) · Cytarabine (5) · thymoglobulin (5) · Mycophenolic Acid (4) · Rituximab (4)
St. Jude Children's Research Hospital (7) · National Heart, Lung, and Blood Institute (NHLBI) (5) · Telik (4) · Gamida Cell ltd (3) · Novartis Pharmaceuticals (3) · AbbVie (2) · Assistance Publique - Hôpitaux de Paris (2) · Center for International Blood and Marrow Transplant Research (2) · Fred Hutchinson Cancer Center (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Institut de Recherches Internationales Servier (2) · Jazz Pharmaceuticals (2) · National Cancer Institute (NCI) (2) · Amgen (1) · Amphivena Therapeutics, Inc. (1)
United States (72) · France (12) · Germany (11) · Australia (9) · Spain (9) · Canada (7) · Italy (7) · United Kingdom (6) · Belgium (5) · Netherlands (5) · China (4) · Israel (4) · Japan (4) · Singapore (4) · Poland (3)
Brandon Triplett, MD (3) · Mitchell Horwitz, MD (3) · Gail Brown, MD (2) · Gail L Brown, MD (2) · Joanne Kurtzberg, MD (2) · Amy Hobeika, PhD (1) · Andrea Toma, MD, PhD (1) · Andrew Artz, MD (1) · Andrew Wei, MBBS, PhD (1) · Annie Im, MD (1) · Anoop K Enjeti, MBBS FRCP FRCPA PhD (1)
PMID 17875804, PMID 19398716, PMID 21134985, PMID 21742281, PMID 22198152, PMID 22524974, PMID 24911148, PMID 26991631, PMID 27507877, PMID 27736729, PMID 27760758, PMID 30523748, PMID 31098682, PMID 31151984, PMID 32706891, PMID 33194741, PMID 33811823, PMID 33905264, PMID 34157093, PMID 34351368, PMID 36095125, PMID 36260765, PMID 36881782, PMID 37120136, PMID 37530627, PMID 37703995, PMID 38065202, PMID 38259250, PMID 41348911, PMID 41792302, PMID 42617873
2014 (2), 2009 (1), 2016 (1), 2018 (1), 2023 (1)